» Articles » PMID: 33536876

Microvascular Alterations in Alzheimer's Disease

Overview
Specialty Cell Biology
Date 2021 Feb 4
PMID 33536876
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder associated with continual decline in cognition and ability to perform routine functions such as remembering familiar places or understanding speech. For decades, amyloid beta (Aβ) was viewed as the driver of AD, triggering neurodegenerative processes such as inflammation and formation of neurofibrillary tangles (NFTs). This approach has not yielded therapeutics that cure the disease or significant improvements in long-term cognition through removal of plaques and Aβ oligomers. Some researchers propose alternate mechanisms that drive AD or act in conjunction with amyloid to promote neurodegeneration. This review summarizes the status of AD research and examines research directions including and beyond Aβ, such as tau, inflammation, and protein clearance mechanisms. The effect of aging on microvasculature is highlighted, including its contribution to reduced blood flow that impairs cognition. Microvascular alterations observed in AD are outlined, emphasizing imaging studies of capillary malfunction. The review concludes with a discussion of two therapies to protect tissue without directly targeting Aβ for removal: (1) administration of growth factors to promote vascular recovery in AD; (2) inhibiting activity of a calcium-permeable ion channels to reduce microglial activation and restore cerebral vascular function.

Citing Articles

Retinal vascular changes are associated with PET-based biomarkers of Alzheimer's disease: A pilot study.

Leung K, Chan V, Lam B, Mok V, Cheung C J Alzheimers Dis Rep. 2025; 8(1):1639-1648.

PMID: 40034363 PMC: 11863728. DOI: 10.1177/25424823241300416.


evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease.

Cummings J, Atri A, Feldman H, Hansson O, Sano M, Knop F Alzheimers Res Ther. 2025; 17(1):14.

PMID: 39780249 PMC: 11708093. DOI: 10.1186/s13195-024-01666-7.


Diagnostic value of arterial spin labeling for Alzheimer's disease: A systematic review and meta-analysis.

Zhang X, Zhang H, Bao Q, Yin Z, Li Y, Xia M PLoS One. 2024; 19(11):e0311016.

PMID: 39570963 PMC: 11581220. DOI: 10.1371/journal.pone.0311016.


Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer's Disease.

Bonomi C, Motta C, Di Donna M, Poli M, Nuccetelli M, Bernardini S Alzheimers Res Ther. 2024; 16(1):248.

PMID: 39550595 PMC: 11568584. DOI: 10.1186/s13195-024-01617-2.


Iron accumulation/overload and Alzheimer's disease risk factors in the precuneus region: A comprehensive narrative review.

Mohammadi S, Ghaderi S, Fatehi F Aging Med (Milton). 2024; 7(5):649-667.

PMID: 39507230 PMC: 11535174. DOI: 10.1002/agm2.12363.


References
1.
Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N . Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64(9):1553-62. DOI: 10.1212/01.WNL.0000159740.16984.3C. View

2.
de Jesus R de Paula V, Guimaraes F, Diniz B, Forlenza O . Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?. Dement Neuropsychol. 2017; 3(3):188-194. PMC: 5618972. DOI: 10.1590/S1980-57642009DN30300003. View

3.
Iadecola C, Zhang F, Niwa K, Eckman C, Turner S, FISCHER E . SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci. 1999; 2(2):157-61. DOI: 10.1038/5715. View

4.
Belrose J, Jackson M . TRPM2: a candidate therapeutic target for treating neurological diseases. Acta Pharmacol Sin. 2018; 39(5):722-732. PMC: 5943913. DOI: 10.1038/aps.2018.31. View

5.
Henderson V, Brinton R . Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy. Prog Brain Res. 2010; 182:77-96. PMC: 5776041. DOI: 10.1016/S0079-6123(10)82003-5. View